Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus

Clinical and Experimental Immunology

Volumn 125, Issue 1, 2001, Pages 149-154

  Frijns, C J M ^a   Derksen, R H W M ^a   De Groot, Ph G ^a   Algra, A ^a   Fijnheer, R ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Endothelial cell; Lupus anticoagulant; SLE; Thrombosis

Indexed keywords

CARDIOLIPIN ANTIBODY; CHOLESTEROL; CREATININE; FIBRONECTIN; HOMOCYSTEINE; LUPUS ANTICOAGULANT; PADGEM PROTEIN; THROMBOMODULIN; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; AGE; AMINO ACID BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CELL ACTIVATION; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CREATININE BLOOD LEVEL; DISEASE ACTIVITY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM;

ADULT; BIOLOGICAL MARKERS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; THROMBOSIS;

EID: 0034895070     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2001.01520.x     Document Type: Article

References (34)

1. Thrombosis and systemic lupus erythematosus. Hopkins Lupus Cohort Perspective
2. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus
3. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus - A meta-analysis
4. Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: A retrospective cohort study
5. Activation of cultured vascular endothelial cells by antiphospholipid antibodies
6. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal antibeta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation
7. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro
8. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo
9. Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis
10. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study
11. Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus. Relationship with Raynaud's phenomenon, disease activity, inflammatory indices, anticardiolipin antibodies and corticosteroid therapy
12. Serum thrombomodulin and anticardiolipin antibodies in patients with systemic lupus erythematosus
13. Plasma thrombomodulin as a marker of vascular injuries in collagen vascular diseases
14. Clinical significance of serum thrombomodulin levels in patients with systemic rheumatic diseases
15. The origin of P-selectin as a circulating plasma protein
16. Soluble adhesion molecules reflect endothelial cell activation in ischemic stroke and in carotid atherosclerosis
17. Soluble P-selectin in the plasma of patients with connective tissue diseases
18. Human endothelial cells synthesize, process and secrete fibronectin molecules bearing an alternatively spliced type III homology (ED1)
19. Levels of circulating cellular fibronectin are increased in patients with rheumatoid arthritis
20. The 1982 revised criteria for the classification of systemic lupus erythematosus
21. Derivation of the SLEDAI. A disease activity index for lupus patients
22. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies
23. Von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura
24. Detection of platelet activation using activation specific monoclonal antibodies
25. Immunohistochemistry of the intercellular matrix components and the epithelio-mesenchymal junction of the human tooth germ
26. Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus
27. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: Correlations with the severity of thrombosis
28. Antiphospholipid antibodies, haemostatic variables and thrombosis - A survey of 144 patients
29. Endothelium-derived haemostatic factors and the antiphospholipid syndrome
30. Stimulation of von Willebrand factor antigen release by immunoglobulin from thrombosis prone patients with systemic lupus erythematosus and the anti-phospholipid syndrome
31. Increase in plasma thrombomodulin in lupus erythematosus with antiphospholipid antibodies
32. Increased factor VIIa levels in systemic lupus erythematosus patients with lupus anticoagulant
33. Plasma thrombomodulin as an indicator of thromboembolic disease in systemic lupus erythematosus
34. Antiphospholipid antibodies activate vascular endothelial cells